Solar Panels for
Pharmaceutical Plants
GMP Compliant Installations
Specialist installations for pharmaceutical manufacturing. Clean room HVAC loads with 24/7 critical operations. Zero contamination risk, MHRA approved processes.
Pharmaceutical Energy Profile
Pharma facilities require constant climate control, clean room operations, and 24/7 critical systems
HVAC Systems
Clean room climate control & air handling
Critical Operations
Continuous sterile manufacturing
Clean Room Classes
Varying contamination control needs
Typical System
Large-scale for pharma plants
GMP Compliance & Installation Protocols
Critical Considerations
- Zero Contamination Risk: Roof work doesn't compromise clean rooms
- Shutdown Scheduling: Installation during planned maintenance windows
- MHRA Documentation: Full validation and change control procedures
- Critical Systems Protection: No disruption to sterile operations
Energy Breakdown
ROI for Pharmaceutical Manufacturing
High energy consumption makes pharma facilities ideal for solar investment
24/7 operations maximize solar ROI through constant daytime usage
Typical 300kW system for mid-size pharmaceutical plant
Significant grid electricity offset during production hours
EU GMP Annex 1 Compliance & Cleanroom Classifications
The revised EU GMP Annex 1 (implemented August 2023) fundamentally changes how contamination risk must be managed during facility modifications, including solar installations.
Contamination Control Strategy (CCS) Requirement
Under the 2023 revision, all sterile manufacturing facilities must maintain a documented Contamination Control Strategy. Any facility modification — including rooftop solar installation — must be assessed against this CCS and undergo formal change control review before works commence.
Our pre-installation assessment includes: CCS gap analysis, risk assessment against EU GMP Annex 1 Section 4, particle baseline measurement (≥0.5μm and ≥5.0μm per ISO 14644-1), and formal change control documentation for your QA team.
Cleanroom Grade Impact Assessment
The EU GMP classification system grades cleanrooms A through D. Each grade requires different installation protocols when working on adjacent or overhead structures.
| EU GMP Grade | ISO Equivalent | Typical Use | Installation Protocol | Downtime Required |
|---|---|---|---|---|
| Grade A | ISO 5 | Aseptic fill/finish, open product | Works only during validated shutdown; full re-qualification required | Full facility shutdown |
| Grade B | ISO 7 (at rest) | Background to Grade A; aseptic prep | Isolated clean bay shutdown; positive pressure maintained | Partial shutdown by zone |
| Grade C | ISO 8 | Less critical sterile operations, filling buffer | Continuous particle monitoring; sequential zonal approach | Zonal shutdown only |
| Grade D | ISO 8+ | Non-sterile primary packaging, dispensing | Standard industrial protocols with containment barriers | Minimal/none |
Our GMP Installation Protocol
-
1
Pre-Works CCS Review: Formal change control submission to client QA team; risk assessment against applicable Annex 1 sections
-
2
Particle Baseline Measurement: ISO 14644-2 compliant pre-works sampling across all affected grades; data submitted to client QA
-
3
Sealed Penetration Works: All roof penetrations sealed with validated BS EN ISO 9001:2015 materials; pressure differential verification before and after
-
4
Post-Works Requalification: ISO 14644-2 particle count verification; HVAC pressure differential testing; filter integrity checks per EN 1822
-
5
IQ/OQ/PQ Documentation Package: Full validation dossier provided within 10 working days; MHRA audit-ready format
Validation Documentation Scope
Design specification conformance; component traceability certificates; calibration records for all metering equipment; as-built drawings to BS EN 62446-1:2016
System performance under normal/abnormal conditions; grid connection commissioning record per G99; protective relay test records; inverter performance verification
90-day monitored performance period; half-hourly generation data; export metering accuracy verification; yield ratio vs. modelled prediction (target ≥95% PR)
All computerised systems (monitoring, SCADA, generation analytics) documented per GAMP 5 Category 4/5 software guidelines where applicable
UK Pharmaceutical Manufacturing Clusters
The UK pharmaceutical sector operates across several defined manufacturing clusters, each with distinct energy profiles and solar potential.
Cheshire / Macclesfield Corridor
Home to AstraZeneca's global API manufacturing headquarters at Macclesfield, alongside Almac Group and Bayer facilities. Large-scale continuous manufacturing processes with 24/7 critical HVAC loads.
Cambridge Biomedical Campus
Europe's largest centre for medical research and health science. Continuous laboratory HVAC loads, autoclave cycles, and cold chain refrigeration drive high daytime electricity demand — ideally matched to solar generation profiles.
East Midlands Pharma Belt
Loughborough, Leicester, and Coventry host significant tablet/capsule manufacturing operations. Batch processing loads create predictable daytime energy demand peaks well-suited to solar offset.
Merseyside / North West
Liverpool and Warrington are home to contract manufacturing organisations (CMOs) and OTC pharmaceutical producers. Warrington's Almac facilities and Liverpool's biotech incubators represent growing solar opportunity.
Scotland (Ulverston / Irvine)
Dechra's Ulverston site and Irvine's established pharma cluster benefit from Smart Export Guarantee (SEG) payments alongside grid savings. Scotland's renewable electricity grid means lower carbon intensity for exported power.
Hertfordshire / Home Counties
Welwyn Garden City (GSK legacy sites), Hatfield, and Stevenage host a concentration of biopharma and diagnostics manufacturers. Proximity to London increases grid electricity costs, improving solar ROI.
Pharmaceutical Solar Case Studies
Detailed examples of pharmaceutical solar installations across facility types — from API manufacturing to sterile fill/finish.
API Manufacturing Facility — Cheshire
Grade B/C cleanrooms; continuous 24/7 operations; 450kW system
This continuous API manufacturing site required installation during a planned annual maintenance shutdown to maintain Grade B cleanroom certification. The 450kW system was installed across two roof sections in 8 working days. The facility's 24/7 continuous operations mean daytime solar generation is consumed almost entirely on-site, with near-zero export, maximising the avoided grid tariff benefit.
Key GMP Challenge Solved:
The inverter room was located adjacent to a Grade C dispensing suite. Cable routing required sealed cable tray installations through three fire compartments with intumescent sealing to BS EN 1366-3. All penetrations included in the IQ documentation and verified post-installation.
Sterile Fill/Finish Facility — Hertfordshire
Grade A/B fill lines; parenteral manufacturing; 280kW system
Sterile fill/finish operations require Grade A laminar airflow conditions in the immediate fill zone, with Grade B background environment. This installation was the most technically demanding we have undertaken in the pharmaceutical sector. All roof works were scheduled during a 12-day planned product changeover. A specialist particle monitoring contractor was engaged to provide continuous real-time ISO 14644-2 monitoring throughout the installation period.
MHRA Inspection Outcome:
The facility underwent an unannounced MHRA inspection 4 months after installation. The installation change control, IQ/OQ/PQ documentation, and particle monitoring records were reviewed with no observations raised regarding the solar installation. The QA director confirmed the documentation package was "exemplary" in their post-inspection debrief.
Pharmaceutical R&D Campus — Cambridge
Multiple lab buildings; non-sterile API research; 3 × 120kW systems
This R&D campus installation was structured as three separate projects across 18 months, allowing each building's change control process to proceed independently. The phased approach also allowed the first building's commissioning data to inform inverter sizing for subsequent buildings. Laboratory HVAC (running year-round for temperature and humidity control) provided excellent daytime load match to solar generation.
Capital Allowances Outcome:
The client's tax advisers confirmed all three systems qualified for Annual Investment Allowance (AIA), providing 100% first-year tax deduction in the year of installation. The phased approach meant the first two systems were installed in different tax years, enabling AIA to be applied in full across two financial years rather than one.
Regulatory Compliance: MHRA, SECR & ESOS
Pharmaceutical manufacturers face a unique intersection of manufacturing quality regulation and energy/environmental reporting obligations.
MHRA GMP Compliance
Solar installation on licensed pharmaceutical manufacturing sites requires change control under the site's Pharmaceutical Quality System (PQS). Our process integrates with your existing change management procedure.
- •Change control documentation to ICH Q10 standard
- •Risk assessment against EU GMP Chapter 3 (Premises)
- •Post-installation review documentation provided
- •All deviations captured and CAPA records provided
SECR Reporting Benefits
Streamlined Energy and Carbon Reporting (SECR) is mandatory for large UK companies (250+ employees or £36M+ turnover). Solar generation provides independently verifiable Scope 2 emission reductions.
- •Half-hourly generation data for SECR calculation
- •Scope 2 location-based and market-based metrics
- •Export metering data for consumed vs. exported split
- •Annual generation certificates for sustainability reports
ESOS Phase 4 Interaction
Most large pharmaceutical manufacturers qualify under ESOS Phase 4 (qualification date: 31 December 2026). Installing solar before the qualification date reduces your measured energy consumption baseline, which can affect the scope of required ESOS action plan measures.
- •Solar reduces kWh consumed in ESOS baseline period
- •Half-hourly metering satisfies ESOS evidence requirements
- •Demonstrates action against ESOS recommendations
- •Read our full ESOS Phase 4 solar guide
Science Based Targets & Net Zero Supply Chain Requirements
Major pharmaceutical companies are increasingly requiring Scope 3 supply chain emissions data as part of supplier qualification. If your facility supplies AstraZeneca, GSK, Pfizer, or other SBTi-committed companies, demonstrable Scope 2 reductions through solar generation can protect your supplier status.
SBTi-Committed Pharma Companies (Scope 3 Requirements):
- AstraZeneca — Ambition Zero Carbon target, Scope 3 supplier engagement
- GSK — net zero supply chain by 2030 programme
- Reckitt — Carbon Disclosure Project (CDP) supplier ratings
- Johnson & Johnson — Carbon Neutrality goal supplier requirements
Solar's Role in Supplier Compliance:
- Reduces Scope 2 market-based emissions (verifiable via EACs)
- Improves CDP score submitted in supplier questionnaires
- Demonstrates climate action in PSCI supplier audit framework
- Supports ISO 50001 energy management system certification
Frequently Asked Questions
Technical and regulatory questions answered by our pharmaceutical solar specialists.
Are solar installations GMP compliant for pharmaceutical facilities? ▼
Yes. Pharmaceutical solar installations are designed to meet GMP requirements under EU GMP Chapter 3 (Premises and Equipment) and MHRA standards. All installation procedures maintain clean room integrity through validated materials, sealed work areas, and continuous particle monitoring. Full IQ/OQ/PQ documentation is provided for regulatory audit. Zero contamination incidents across all pharmaceutical installations.
What does EU GMP Annex 1 (2022/2023) mean for solar installations? ▼
The revised EU GMP Annex 1 (August 2023 implementation) requires sterile manufacturers to maintain a documented Contamination Control Strategy (CCS). Any facility modification — including rooftop solar — must be formally assessed against this CCS. Our pre-installation process includes a CCS gap analysis, formal change control submission, pre-works particle baseline measurement per ISO 14644-2, and post-installation requalification sampling. All records are provided in MHRA audit-ready format.
Can solar power critical clean room HVAC systems 24/7? ▼
Solar systems power pharmaceutical HVAC loads during daylight hours, with grid electricity maintaining operations overnight and on low-irradiance days. Systems are sized for continuous HVAC loads — clean room air handling (ISO 5-8 classifications), temperature/humidity control, and HEPA filtration. The grid connection is maintained as primary supply; solar provides offset rather than primary power, ensuring no risk to critical environmental controls. Typical 500kW–1MW installations offset 40–60% of annual HVAC energy costs.
What validation documentation is provided? ▼
Full IQ/OQ/PQ documentation is provided. Installation Qualification (IQ) covers design specification, component traceability, and calibration records to BS EN 62446-1:2016. Operational Qualification (OQ) covers grid connection commissioning per G99 and inverter performance verification. Performance Qualification (PQ) covers a 90-day monitored performance period with half-hourly generation data. All computerised systems are documented per GAMP 5 guidelines. Documentation is provided within 10 working days of commissioning.
How does solar interact with ESOS Phase 4 compliance? ▼
Most large pharmaceutical manufacturers qualify under ESOS Phase 4 (qualification date: 31 December 2026). Installing solar before this date reduces your measured energy consumption baseline, which can affect the scale of required ESOS action plan measures. Half-hourly metering data from the solar system satisfies ESOS evidence requirements for your lead energy assessor. We recommend reading our full ESOS Phase 4 solar compliance guide for detailed guidance.
What capital allowances are available for pharmaceutical solar? ▼
Solar panels are classified as special rate assets under s.104A Capital Allowances Act 2001 (HMRC CA23153). The primary relief is Annual Investment Allowance (AIA): 100% first-year deduction on the first £1 million of qualifying expenditure per tax year. For systems exceeding £1M, the 50% First Year Allowance (FYA, made permanent in Autumn 2023) applies to the excess. Full expensing does not apply to solar. See our detailed capital allowances guide for worked examples with your system size.
4.9 / 5 — 287 verified installation reviews
What Pharma Manufacturers Say
"GMP compliance was the hardest part to navigate. The team understood cleanroom power integrity and worked around our validation cycles to avoid any GMP events. 300kW installed across our main production building. No deviations, no complaints. And our energy costs dropped by 41%."
Dr. A. Chatterjee
Facilities Director, UK Licensed Pharmaceutical Manufacturer
300kW system — GMP-compliant installation — 41% energy cost reduction
"Secondary packaging runs 24/5 with strict environmental controls. We were worried about power quality during installation — we needn't have been. Phase transition was seamless and the monitoring portal now shows our Scope 2 reduction in real time, which feeds directly into our sustainability report."
Lisa H.
Head of Operations, Pharmaceutical Packaging Facility
200kW — real-time monitoring — Scope 2 data integrated into ESG reporting
Get Your GMP Compliant Solar Assessment
Free consultation for pharmaceutical manufacturing facilities
Pharmaceutical Manufacturing Solar Service Areas
We install commercial solar panels on pharmaceutical manufacturing facilities and clean rooms across the UK. Our experienced team delivers turnkey solar solutions nationwide.
London & South East
Midlands
North of England
What Our Clients Say
Real feedback from UK manufacturers who've made the switch to solar
"Outstanding GMP-compliant installation at our API manufacturing facility in Cambridge. Zero contamination risk, full validation documentation provided, MHRA audit ready. 450kW system is perfect for our cleanroom HVAC loads. Exceptional professionalism."
Dr. Catherine Hughes
"Pharmaceutical-grade installation for our sterile manufacturing facility. They understood our validation requirements and provided complete IQ/OQ documentation. System supports our sustainability targets while maintaining GMP compliance throughout."
Richard Foster
"Excellent work on our pharmaceutical R&D facility. Installation met all regulatory requirements for cleanroom environments. Now generating 70% of our daytime electricity needs. ESG reporting benefits are substantial."
Amanda Preston
Our Installation Partners & Related Resources
We work with trusted MCS certified installers across the UK and provide resources for every commercial solar need.
MCS Certified Installation Partners
ALPS Electrical
Teesside, North East & Yorkshire. MCS, NAPIT, TrustMark, Tesla Certified. 375+ five-star reviews.
Midland Solar
West Midlands & Warwickshire. MCS, NAPIT certified. #1 ranked solar installer in the Midlands.
Green Hat Renewables
East Anglia — Norfolk, Suffolk, Essex & Cambridgeshire. MCS, RECC Member, Gas Safe Registered.
Solent Solar
Hampshire — Southampton, Winchester, Portsmouth & beyond. MCS Certified, HIES Member.
YEERS
UK-Wide coverage. Commercial solar, building retrofit and heat pump installations.
Sola UK
Hertfordshire, Bedfordshire, London & Home Counties. MCS Certified.
Related Commercial Solar Resources
Costs, Finance & Grants
EPC & Compliance
Our SEO Partner: SEO Dons — Specialist SEO for Solar & Electrical Companies
Continue Reading — Related Topics
Hand-picked guides covering the most relevant adjacent areas to this page.